May 8, 2025 - 19:53

Edgewise Therapeutics has announced encouraging top-line results from its Phase 2 CIRRUS-HCM trial of EDG-7500, a treatment aimed at addressing Hypertrophic Cardiomyopathy (HCM). This trial is a significant step forward in the development of therapies for this serious heart condition, which affects a substantial number of individuals worldwide. The positive outcomes from the trial highlight the potential of EDG-7500 to improve the lives of patients suffering from HCM.
In addition to the promising trial results, the company has reported a strengthened balance sheet, reflecting a net increase in financial resources. This improvement positions Edgewise Therapeutics favorably for future research and development efforts. The combination of successful clinical trial outcomes and a robust financial foundation underscores the company's commitment to advancing innovative treatments in the cardiovascular space. Investors and stakeholders will be keenly watching how these developments unfold in the coming months as the company continues to push forward with its strategic initiatives.
August 20, 2026 - 21:50
Roundup: ExxonMobil / SBA workforce initiative / New HoganTaylor CEOA Texas Business Court judge has thrown out antitrust claims filed by Clean Hydrogen Works against ExxonMobil`s Denbury subsidiary. The ruling states that Texas courts do not have the authority to...
August 20, 2026 - 04:32
Veteran clubs and businesses in Pittsburgh area rally in support of "skill games"At a gathering outside a VFW post in West Mifflin, several veterans argued that the games fund building repairs, utility bills, and community events that would otherwise disappear. `We are not...
August 19, 2026 - 22:28
Roundup: Partnership CEO search / Broadband expansion / Tariff negotiationsThe Greater Baton Rouge Economic Partnership is moving forward with its leadership transition, with officials now saying they expect to have a new chief executive in place within the next three to...
August 19, 2026 - 02:49
From heated rivalry to frenemies: Inside the cutthroat business of ruling tech in AsiaThe next time you scroll through social media on a smartphone or ask an AI assistant for a recipe, think about this: the device in your hand and the software running it are pieces in a much larger,...